Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model

NeuroImage

Volumn 56, Issue 3, 2011, Pages 1027-1034

  Cheng, Yong ^a   Peng, Qi ^a   Hou, Zhipeng ^a   Aggarwal, Manisha ^a   Zhang, Jiangyang ^a   Mori, Susumu ^a,b   Ross, Christopher A ^a   Duan, Wenzhen ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

Biomarker; Brain atrophy; Huntington's disease; LDDMM; MRI; SSRI

Indexed keywords

SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOANALYSIS; BRAIN ATROPHY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC VALUE; DISEASE MODEL; FEMALE; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOUSE; NEOCORTEX; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGING; ANIMALS; ATROPHY; BEHAVIOR, ANIMAL; BRAIN; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DNA; FEMALE; GENOTYPE; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MOVEMENT; NEUROPROTECTIVE AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAMPLE SIZE; SURVIVAL ANALYSIS;

EID: 79955466394     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.02.022     Document Type: Article

References (37)

1. Aggarwal M., Zhang J., Miller M.I., Sidman R.L., Mori S. Magnetic resonance imaging and micro-computed tomography combined atlas of developing and adult mouse brains for stereotaxic surgery. Neuroscience 2009, 162:1339-1350.
2. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
3. Aylward E.H., Codori A.M., Rosenblatt A., Sherr M., Brandt J., Stine O.C., Barta P.E., Pearlson G.D., Ross C.A. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov. Disord. 2000, 15:552-560.
4. Aylward E.H., Li Q., Stine O.C., Ranen N., Sherr M., Barta P.E., Bylsma F.W., Pearlson G.D., Ross C.A. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997, 48:394-399.
5. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
6. Bartzokis G., Lu P.H., Tishler T.A., Fong S.M., Oluwadara B., Finn J.P., Huang D., Bordelon Y., Mintz J., Perlman S. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 2007, 32:1655-1664.
7. Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L., Rubinsztein D.C., Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 2006, 47:215-222.
8. Davatzikos C. Why voxel-based morphometric analysis should be used with great caution when characterizing group differences. Neuroimage 2004, 23:17-20.
9. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., Zhao M., Cadet J.L., Wong J., Ross C.A. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 2008, 30:312-322.
10. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
11. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
12. Genovese C.R., Lazar N.A., Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002, 15:870-878.
13. Gomez-Tortosa E., MacDonald M.E., Friend J.C., Taylor S.A., Weiler L.J., Cupples L.A., Srinidhi J., Gusella J.F., Bird E.D., Vonsattel J.P., Myers R.H. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 2001, 49:29-34.
14. Halliday G.M., McRitchie D.A., Macdonald V., Double K.L., Trent R.J., McCusker E. Regional specificity of brain atrophy in Huntington's disease. Exp. Neurol. 1998, 154:663-672.
15. Harris G.J., Aylward E.H., Peyser C.E., Pearlson G.D., Brandt J., Roberts-Twillie J.V., Barta P.E., Folstein S.E. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch. Neurol. 1996, 53:316-324.
16. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122(Pt 9):1667-1678.
17. Harris G.J., Pearlson G.D., Peyser C.E., Aylward E.H., Roberts J., Barta P.E., Chase G.A., Folstein S.E. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann. Neurol. 1992, 31:69-75.
18. Hobbs N.Z., Barnes J., Frost C., Henley S.M., Wild E.J., Macdonald K., Barker R.A., Scahill R.I., Fox N.C., Tabrizi S.J. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol. 2010, 31:1036-1041.
19. Hobbs N.Z., Henley S.M., Ridgway G.R., Wild E.J., Barker R.A., Scahill R.I., Barnes J., Fox N.C., Tabrizi S.J. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J. Neurol. Neurosurg. Psychiatry 2010, 81:756-763.
20. Kassubek J., Bernhard Landwehrmeyer G., Ecker D., Juengling F.D., Muche R., Schuller S., Weindl A., Peinemann A. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. NeuroReport 2004, 15:363-365.
21. Kloppel S., Henley S.M., Hobbs N.Z., Wolf R.C., Kassubek J., Tabrizi S.J., Frackowiak R.S. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience 2009, 164:205-219.
22. Maheswaran S., Barjat H., Bate S.T., Aljabar P., Hill D.L., Tilling L., Upton N., James M.F., Hajnal J.V., Rueckert D. Analysis of serial magnetic resonance images of mouse brains using image registration. Neuroimage 2009, 44:692-700.
23. Miller M.I., Trouve A., Younes L. On the metrics and Euler-Lagrange equations of computational anatomy. Annu. Rev. Biomed. Eng. 2002, 4:375-405.
24. Nopoulos P.C., Aylward E.H., Ross C.A., Johnson H.J., Magnotta V.A., Juhl A.R., Pierson R.K., Mills J., Langbehn D.R., Paulsen J.S. Cerebral cortex structure in prodromal Huntington disease. Neurobiol. Dis. 2010, 40:544-554.
25. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79:874-880.
26. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., Nopoulos P.C. Brain structure in preclinical Huntington's disease. Biol. Psychiatry 2006, 59:57-63.
27. Paulsen J.S., Nopoulos P.C., Aylward E., Ross C.A., Johnson H., Magnotta V.A., Juhl A., Pierson R.K., Mills J., Langbehn D., Nance M. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res. Bull. 2010, 82:201-207.
28. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C.A., Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 2008, 210:154-163.
29. Reading S.A., Yassa M.A., Bakker A., Dziorny A.C., Gourley L.M., Yallapragada V., Rosenblatt A., Margolis R.L., Aylward E.H., Brandt J., Mori S., van Zijl P., Bassett S.S., Ross C.A. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res. 2005, 140:55-62.
30. Rosas H.D., Goodman J., Chen Y.I., Jenkins B.G., Kennedy D.N., Makris N., Patti M., Seidman L.J., Beal M.F., Koroshetz W.J. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001, 57:1025-1028.
31. Rosas H.D., Lee S.Y., Bender A.C., Zaleta A.K., Vangel M., Yu P., Fischl B., Pappu V., Onorato C., Cha J.H., Salat D.H., Hersch S.M. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage 2010, 49:2995-3004.
32. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 2006, 21:1317-1325.
33. Sawiak S.J., Wood N.I., Williams G.B., Morton A.J., Carpenter T.A. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2009, 33:12-19.
34. Sawiak S.J., Wood N.I., Williams G.B., Morton A.J., Carpenter T.A. Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol. Dis. 2009, 33:20-27.
35. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., Kennard C., Hicks S.L., Fox N.C., Scahill R.I., Borowsky B., Tobin A.J., Rosas H.D., Johnson H., Reilmann R., Landwehrmeyer B., Stout J.C. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8:791-801.
36. Wild E.J., Henley S.M., Hobbs N.Z., Frost C., MacManus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. Mov. Disord. 2010, 25:888-895.
37. Zhang J., Peng Q., Li Q., Jahanshad N., Hou Z., Jiang M., Masuda N., Langbehn D.R., Miller M.I., Mori S., Ross C.A., Duan W. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 2010, 49:2340-2351.